<IF_12>
  rdf:type ifo:IF_12 ;
  ifo:key "ⅩⅡ.  参考資料 " .

<IF_12_1>
  rdf:type ifo:IF_12_1 ;
  ifo:key "1.主な外国での発売状況 " ;
  ifo:value """
  世界 81 の国と地域で承認 (2019 年 5 月現在)
  """ .

<IF_12_1_1>
  rdf:type ifo:IF_12_1_1 ;
  ifo:key "本邦" ;
  ifo:効能・効果　"""
  過活動膀胱における尿意切迫感、頻尿及び切迫性尿失禁

　注意事項：
    1 本剤を適用する際、十分な問診により臨床症状を確認するとともに、類似の症状を呈する疾患(尿路感染症、尿路結石、膀胱癌や前立腺癌などの下部尿路における新生物等)があることに留意し、尿検査等により除外診断を実施すること。なお、必要に応じて専門的な検査も考慮すること。
    2 下部尿路閉塞疾患(前立腺肥大症等)を合併している患者では、それに対する治療(α1 遮断薬等)を優先させること。
  """ ;
  ifo:用法・用量 """
　通常、成人にはミラベグロンとして 50mg を 1 日 1 回食後に経口投与する。
　
　注意事項：
    1 中等度の肝機能障害患者(Child-Pugh スコア 7~9)への投与は 1 日 1 回 25mg から開始する。 
    2 重度の腎機能障害患者(eGFR15~29mL/min/1.73m2)への投与は 1 日 1 回 25mg から開始する。
  """ .
    ## 安倍さんチェック

<IF_12_1_2>
  rdf:type ifo:IF_12_1_2 ;
  ifo:key "米国" ;
  ifo:販売名 "MYRBETRIQ" ;
  ifo:剤形・規格・容量  "Extended-release tablets: 25 mg and 50 mg" ;
  ifo:販売企業名 "Astellas Pharma US Inc." ;
  ifo:発売年月 2012-10 ;
  ifo:効能・効果 """
  The treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
  """ ;
  ifo:用法・用量 """
  ・Recommended starting dose is 25 mg once daily, alone or in combination with solifenacin succinate 5 mg, once daily.
  ・Based on individual efficacy and tolerability, may increase dose to 50 mg once daily, alone or in combination with solifenacin succinate 5 mg, once daily .
  ・Swallow whole with water, with or without food, do not chew, divide or crush .
  ・Patients with Severe Renal Impairment or Patients with Moderate Hepatic Impairment: Maximum dose is 25 mg MYRBETRIQ once daily.
  ・Patients with End Stage Renal Disease (ESRD) or Patients with Severe Hepatic Impairment: Not recommended.
  """ .

  <IF_12_1_3>
    rdf:type ifo:IF_12_1_3 ;
    ifo:key "EU" ;
    ifo:販売名 "BETMIGA" ;
    ifo:剤形・規格・容量  "prolonged-release tablets: 25 mg and 50 mg" ;
    ifo:販売企業名 "Astellas Pharma Europe B.V." ;
    ifo:発売年月 2013-02 ;
    ifo:効能・効果 """
    Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome.
    """ ;
    ifo:用法・用量 """
    Posology
    Adults (including elderly patients)
    The recommended dose is 50 mg once daily.

    Special populations
    Renal and hepatic impairment
    Betmiga has not been studied in patients with end stage renal disease (GFR < 15 mL/min/1.73 m2 or patients requiring haemodialysis) or severe hepatic impairment (Child-Pugh Class C) and it is therefore not recommended for use in these patient populations.

    The following table provides the daily dosing recommendations for subjects with renal or hepatic impairment in the absence and presence of strong CYP3A inhibitors.
    ###表あり###
    Gender
    No dose adjustment is necessary according to gender.

    Paediatric population
    The safety and efficacy of mirabegron in children below 18 years of age have not yet been established.
    No data are available.

    Method of administration
    The tablet is to be taken with liquids, swallowed whole and is not to be chewed, divided, or crushed. It may be taken with or without food.

      * Interaction with other medicinal products and other forms of interaction
    """ .

<IF_12_2>
 rdf:type ifo:IF_12_2 ;
 ifo:key "2.海外における臨床支援情報 " .

<IF_12_2_1>
  rdf:type ifo:IF_12_2_1 ;
  ifo:value "(1) 妊婦への投与に関する海外情報（FDA、オーストラリア分類）" .

<IF_12_2_1_1>
  rdf:type ifo:IF_12_2_1_1 ;
  ifo:key "日本" ;
  ifo:value """
  日本の添付文書の「9.5妊婦」、「9.6授乳婦」の項の記載は以下のとおりであり、FDA(米国添付文書)、オーストラリア分類とは異なる。本邦における使用上の注意
  9.5妊婦
  妊婦又は妊娠している可能性のある女性には投与しないこと。動物実験(ラット、ウサギ)で、胎児において着床後死亡率の増加、体重低値、肩甲骨等の屈曲及び波状肋骨の増加、骨化遅延(胸骨分節、中手骨、中節骨等の骨化数低値)、大動脈の拡張及び巨心の増加、肺副葉欠損が認められている。
  9.6授乳婦
  授乳を避けさせること。動物実験(ラット)で乳汁移行が認められている。また、授乳期に本薬を母動物に投与した場合、出生児で生存率の低値及び体重増加抑制が認められている。
  """ .

<IF_12_2_1_2>
  rdf:type ifo:IF_12_2_1_2 ;
  ifo:key "米国" ;
  ifo:value """
  米国における添付文書の記載は以下のとおりである。
  8.1 Pregnancy
  Risk Summary
  There are no studies with the use of MYRBETRIQ in pregnant women to inform drug-associated risk for birth defects or miscarriage. Mirabegron administration to pregnant animals during organogenesis resulted in reversible skeletal variations (in rats) at 22-fold (via AUC) the maximum recommended human dose (MRHD) of 50 mg/day and decreased fetal body weights (in rabbits) at 14-fold the MRHD. At maternally toxic exposures in rats (96-fold), decreased fetal weight and increased fetal mortality were observed and, in rabbits (36-fold), cardiac findings (fetal cardiomegaly and fetal dilated aortae) were observed.
  The estimated background risks of major birth defects and miscarriage for the indicated populations are unknown. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2-4％ and 15-20％, respectively.
  Data
  Animal Data
  No embryo-fetal lethality or morphological fetal developmental abnormalities were produced in pregnant rats following daily oral administration of mirabegron during the period of organogenesis (Days 7 to 17 of gestation) at 0, 10, 30, 100, or 300 mg/kg, doses which were associated with systemic exposures (AUC) 0, 1, 6, 22 and 96-fold the MRHD. Skeletal variations (wavy ribs, delayed ossification) were observed in fetuses at doses 22-fold the systemic exposure at the MRHD and were reversible during development. Exposures 96-fold the MRHD were maternally toxic (mortality, decreased body weight gain) and associated with fetal growth reduction.
  Pregnant rabbits were treated with daily oral doses of mirabegron at 0, 3, 10, or 30 mg/kg/day during the period of organogenesis (Days 6 to 20 of gestation), which resulted in plasma exposures that were 0, 1, 14, or 36-fold the MRHD based on AUC. At 10 mg/kg/day (14-fold the MRHD) and higher, fetal body weights were reduced. At 30 mg/kg/day, maternal toxicity (increased heart rate, mortality, reduced body weight gain, reduced food consumption) occurred, and fetal deaths, fetal cardiomegaly and fetal dilated aortae were observed at systemic exposure levels (AUC) 36-fold the MRHD.
  In a pre-and postnatal developmental study, rats were treated with daily oral doses of mirabegron at 0, 10, 30, or 100 mg/kg/day (0, 1, 6, or 22-fold the MRHD) from day 7 of gestation until day 20 after birth. Decreased maternal body weight was observed along with decreased pup survival in the first few days after birth (92.7％ survival) compared to the control group (98.8％ survival), at 100 mg/kg/day (22-fold the MRHD). Pup body weight gain was reduced until postnatal day 7 but not further affected throughout the remainder of the lactation period. In utero and lactational exposure did not affect developmental milestones, behavior or fertility of offspring. No effects were observed at 30 mg/kg/day.
  8.2 Lactation
  Risk Summary
  There is no information on the presence of mirabegron in human milk, the effects on the breastfed child, or the effects on milk production. Mirabegron-related material was present in rat milk and in the stomach of nursing pups following administrations of a single 10 mg/kg oral dose of 14C-labeled mirabegron to lactating rats.
  The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for MYRBETRIQ and any potential adverse effects on the breastfed child from MYRBETRIQ or from the underlying maternal condition.
  (2018 年 4 月改訂)
  """ .

<IF_12_2_1_3>
  rdf:type ifo:IF_12_2_1_3 ;
  ifo:key "オーストラリア分類" ;
  ifo:value "B3 (2019年6月)" ;
  ifo:＜参考：分類の概要＞ """
  オーストラリア分類：An Australian categorisation of risk of drug use in pregnancy
  B3：Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed.
  Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.
  Australian public assessment for mirabegron
  〈https://www.tga.gov.au/file/1307/download〉(2019/05/17 アクセス)
  """ .

<IF_12_2_2>
  rdf:type ifo:IF_12_2_2 ;
  ifo:value "(2) 小児等に関する記載" .

<IF_12_2_2_1>
  rdf:type ifo:IF_12_2_2_1 ;
  ifo:key "日本" ;
  ifo:value """
  日本の添付文書の記載は以下のとおりであり、米国の添付文書及び英国の SPC とは異なる。
  9.特定の背景を有する患者に関する注意
  9.7小児等
  小児等を対象とした有効性及び安全性を指標とした国内の臨床試験は実施していない。
  """ .

<IF_12_2_2_2>
  rdf:type ifo:IF_12_2_2_2 ;
  ifo:key "米国" ;
  ifo:value """
  The safety and effectiveness of MYRBETRIQ in pediatric patients have not been established.
  (2018年4月)
  """ .

<IF_12_2_2_3>
  rdf:type ifo:IF_12_2_2_3 ;
  ifo:key "英国" ;
  ifo:value """ 
  Paediatric population
  The safety and efficacy of mirabegron in children below 18 years of age have not yet been established.
  No data are available.
  (2019年4月)
  """ .
